Acelrx Pharmaceuticals (ACRX) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Clean Climate Environment Extraction Intensity Materials Nature Offset Package Packaging Pandemic Plastic Raw Materials Toxic Access African American Asian Attrition Benefits Black Collective Bargaining Community Culture Customer Data Privacy Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Employee Retention Engagement Ethnicity Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injury Latinx LGBTQ Opioid Pay Equity Pay for Performance Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workforce Action Plan Assessment Assurance Attorneys General Audit Bonus Bribe Bribery Chronic Class Action Lawsuit Classified Classified Board Commitment Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigant Litigation Long-term Majority Materiality Mission Oversee Oversight Plaintiff Procurement Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Single Trigger Special Meeting Strategy Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The Annual Meeting of the Company was held on June 17, 2021. Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. There were 119,102,999 shares of common stock entitled to vote at the Annual Meeting. A total of 67,447,154 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the Annual Meeting were as follows:

Proposal No. 1

Adrian Adams, Richard Afable, M.D. and Mark G. Edwards were elected as Class I directors, by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2024 Annual Meeting of Stockholders by the following vote:

Nominee	For	Withheld	Broker Non-Votes

Adrian Adams	16,857,411	12,537,395	38,052,348
Richard Afable, M.D.	27,151,962	2,242,844	38,052,348
Mark G. Edwards	27,033,126	2,361,680	38,052,348

In addition to the directors elected above, Vincent J. Angotti, Stephen J. Hoffman, M.D., Ph.D. and Pamela P. Palmer, M.D., Ph.D. will continue to serve as directors until the 2022 Annual Meeting of Stockholders, and Marina Bozilenko, Howard B. Rosen and Mark Wan will continue to serve as directors until the 2023 Annual Meeting of Stockholders, in each case until their successors are elected and qualified, or until their earlier death, resignation or removal.

Proposal No. 2

The selection by the Audit Committee of the Board of OUM & Co. LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021 was ratified by the following vote:


For	Against	Abstain
63,552,880	3,355,894	538,380

Proposal No. 3

The compensation paid to the Company’s named executive officers, as disclosed pursuant to